Regenerative Medicine

Regenerative medicine is a branch of medicine that aims to heal or replace damaged tissues or organs. The types of regenerative medicine treatments include stem cells, platelet-rich plasma, surgical interventions (e.g., reshaping bone), tissue grafting, and prolotherapy. More recently, exosomes - or small extracellular vesicles secreted from cells - with stem cell markers have shown potential as a regenerative therapy option.

Tools to Advance Your Regenerative Medicine Research

Flow Cytometry

C-Series (membrane-based arrays with chemiluminescent detection)

Other Products & Services

RayBiotech also has a large catalog of ELISA kits and other antibody arrays for regenerative medicine research. Full testing services are available for all RayBiotech products.

Need help identifying the right product or service for your study? Contact us at [email protected].

Publications Citing RayBiotech Products

Spinal cord injury (SCI) results in varying levels of motor and sensory deficits, including paraplegia and quadriplegia. Long et al. demonstrate that fetal placental mesenchymal stromal cells (PMSCs) isolated from canine placentas secrete immunomodulatory and neurotrophic paracrine factors (IL-6, IL-8, MCP-1, VEGF). When co-cultured with SH-SY5Y cells, the PMSCs' secretion stimulated the growth of complex neural networks. This work highlight the potential use of PMCSc as a regenerative therapy option for neurological disorders.

Long C, et al. Isolation and characterization of canine placenta‐derived mesenchymal stromal cells for the treatment of neurological disorders in dogs. Cytometry Part A 93.1 (2018). [view publication]
RayBiotech Products: Quantibody (cat no. QAC-CYT-1)
Species: Canine (dog)
Sample Type: Tissue lysate

Extracellular vesicles (EVs) offer an alternative approach to cell-based regenerative medicine. In this study, mice were treated with EVs isolated from human adipose-derived stem cells (HASCs) during white and beige adipogenic differentiation (D-EV and BD-EV, respectively). miRNAs in the BD-EVs altered diet-induced obesity, thus improving diet-related hepatic steatosis and glucose tolerance. These results reveal that EVs can promote cell reprogramming.

Jung YJ, et al. Cell reprogramming using extracellular vesicles from differentiating stem cells into white/beige adipocytes. Sci Adv. (2020). [view publication]
RayBiotech Products: G-Series (cat no. AAH-ADI-G1)
Species: Human
Sample Type: Tissue lysate

Heart tissue repair following myocardial infarction (MI) may be possible with mesenchymal stem cell (MSC) transplantation since MSCs secrete multiple growth factors and immune-modulatory cytokines. However, low cell viability and activity during and post injection have resulted in low therapeutic efficacy. To help address this issue, Choe et al. encapsulated MSCs in graphene oxide/alginate composite microgels (MGOA) with anti-oxidizing activity. MSC viability increased in vitro using MGOA under oxidative stress conditions. In vivo experiments using rats with induced MI showed that the infarction area decreased and cardiac function improved with MGOA treatment. This novel encapsulation system could serve as an effective delivery platform to treat various injuries and diseases with stem cell-based regenerative medicine.

Choe G, et al. Anti-oxidant activity reinforced reduced graphene oxide/alginate microgels: Mesenchymal stem cell encapsulation and regeneration of infarcted hearts. Biomaterials (2019). [view publication]
RayBiotech Products: C-Series (cat no. AAH-GF-1)
Species: Human
Sample Type: Conditioned medium

Ischemic diseases may lead to reduced limb function or loss. Predicting the therapeutic efficacy of using human embryonic stem cells-derived endothelial progenitor cells (hEPCs) in treating limb ischemia would be possible with non-invasive imaging to track transplanted EPCs in ischemic lesions. Lim et al. developed a non-invasive, bioorthogonal labeling strategy of hEPCs for live imaging. Moreover, their labeling strategy did not result in cytotoxicity or functional perturbation in tubular formation, oxygen consumption and paracrine effect of hEPCs in vitro. In mice with induced limb ischemia, the labeled hEPCs were successfully monitored for 28 days with improved blood reperfusion and therapeutic neovascularization effects.

Lim S, et al. Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography. Biomaterials (2021). [view publication]
RayBiotech Products: L-Series (cat no. AAH-BLM-1A)
Species: Human
Sample Type: Conditioned medium

Aortic dissection (AD), which has a high rate of sudden death, can be prevented with surgical intervention. However, identifying patients at risk of AD is limited since the molecular mechanisms underlying AD are not well understood. Since the potential of microRNAs (miRs) as therapeutic targets in vascular disease has been recently demonstrated, Sun et al. demonstrated that miR-27a levels were lower in aortas from AD patients than healthy controls. Inhibition of miR-27a in human umbilical vein endothelial cells (HUVEC) promoted apoptosis, while miR-27a overexpression attenuated apoptosis. Additional experiments showed that miR-27a targets FAS-associated death domain protein (FADD), a protein involved in apoptosis. This study highlights the potential of miR-27a as a biomarker and therapeutic target in AD.

Sun Y, et al. miR-27a regulates vascular remodeling by targeting endothelial cells’ apoptosis and interaction with vascular smooth muscle cells in aortic dissection, Theranostics (2019). [view publication]
RayBiotech Products: C-Series (cat no. AAH-APO-1)
Species: Human
Sample Type: Cell lysate

Pulmonary fibrosis (PF) is a progressive disease in which functional lung compartments are replaced with fibrotic tissue; no effective therapy has been developed to date. Here, rats with induced PF were treated with low and high doses of human umbilical mesenchymal stem cells (HUMSCs) to determine whether this treatment could improve lung regeneration. Rats that received high-dose HUMSCs displayed improved blood oxygen saturation levels, respiratory rates, and alveolar function. Furthermore, the HUMSCs remained viable one month after engraftment. This study demonstrates that HUMSCs can effectively reverse rat PF.

Chu KA, et al. Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly. Theranostics (2019). [view publication]
RayBiotech Products: C-Series (cat no. AAH-CYT-2000)
Species: Human
Sample Type: Tissue lysate